
The combination product is the first to contain “a basal insulin with an ultralong duration of action, and a rapid-acting insulin in a single injection. The researchers conducted an open label study of 447 people with diabetes.
The combination product is the first to contain “a basal insulin with an ultralong duration of action, and a rapid-acting insulin in a single injection. The researchers conducted an open label study of 447 people with diabetes.